Drug Trial Radar · NCT07873801
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Feb 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of the study is to evaluate the efficacy and safety of lebrikizumab treatment for up to 32 weeks in participants with moderate-to-severe face and neck atopic dermatitis (FNAD) who also have moderate-to-severe AD outside of the face and neck region, and who are in need of systemic therapy.
Conditions
- Atopic Dermatitis
Interventions
LebrikizumabDrug
Lebrikizumab SC injection.
PlaceboOther
Matching placebo SC injection.
LebrikizumabDrug
Lebrikizumab for the Placebo-controlled Period who were either responders or non-responders to lebrikizumab treatment at Week 16 will receive lebrikizumab SC injection.
LebrikizumabDrug
Placebo for the Placebo-controlled Period will begin lebrikizumab treatment at Week 16 and will receive lebrikizumab SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving a Face-Investigator Global Assessment (F-IGA) Score of 0 or 1 and a Reduction >=2 Points from Baseline at Week 16Time frame: At Week 16
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.